PAVmed, Inc. PAVMW 深 滬
等待開盤 05-20 09:30:00 美东时间
0.029
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.029
- 總市值 38.69万
- 52周最高 4.743
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.02
- 委 比 0.00%
- 總股本 1334.31万
- 歷史最高 6.94
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.02
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PAVmed Earnings Call: Restructuring Done, Execution Ahead
Pavmed (($PAVM)) has held its Q1 earnings call. Read on for the main highlights...
05-16 08:13
PAVmed Q1 2026 Earnings Call Transcript
PAVmed (NASDAQ:PAVM) reported first-quarter financial results on Friday. The tr...
05-15 22:11
PAVmed Q1 Adj. EPS $(1.17) Misses $(0.70) Estimate, Sales $22.000K Miss $74.000K Estimate.
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(1.17) per share which missed the analyst consensus estimate of $(0.70) by 67.14 percent. This is a 44.29 percent increase over losses of $(2.10) per share from the same
05-15 20:01
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
PAVmed schedules quarterly business update call, to report Q1 results
PAVmed schedules quarterly business update call, to report Q1 results PAVmed scheduled first-quarter 2026 business update conference call and webcast for May 15, 2026 at 8:30 a.m. ET. CEO Lishan Aklog plans to outline operations update and growth strategy on May 15. President and CFO Dennis McGrath
05-01 20:36
Lucid Diagnostics Prices Underwritten Registered Direct Offering Of 18M Common Shares At $1.00 Per Share
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the pricing of an
04-23 20:36
PAVmed files Form 3 initial beneficial ownership statement for Tasso Partners LLC
PAVmed files Form 3 initial beneficial ownership statement for Tasso Partners LLC PAVmed Form 3 filing showed Tasso Partners held 912,996 shares of common stock as of March 27, 2026. Filing identified Tasso Partners as a 10% owner. Disclosure included warrants exercisable since Feb. 3, 2026, expirin
04-07 09:46
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophagea...
04-02 20:01
PAVmed Reports 2025 Results, Strengthens Balance Sheet
An announcement from PAVmed ( ($PAVM) ) is now available. On March 30, 2026, PA...
03-30 21:11
PAVmed Non-GAAP EPS of -$1.05
PAVmed press release (PAVM): Q4 Non-GAAP EPS of -$1.05. PAVmed had cash and cash equivalents of $1.5 million as of December 31, 2025, compared to $1.2 million as of December 31, 2024. For the three mo...
03-30 20:11
